



Press release

Cantargia AB  
Reg. no. 556791-6019  
2015-10-05

## Cantargia: Grant of patent by The European Patent Office (EPO)

**Cantargia AB ("Cantargia") hereby announce that the European Patent Office (EPO) has decided to grant the patent application concerning IL1RAP as a target molecule for antibody therapy and diagnostic methods of leukemia (patent EP2467403). The acknowledgement follow up on the "Intention to Grant" notification, published May 28, 2015.**

Receiving this acknowledgement from EPO means that the company obtains a European protection until year 2029 for the company's method using IL1RAP as target molecule. The protection includes therapy as well as diagnostic methods of leukemia. The patent application is also under review within e.g. USA, Japan and China.

*"IL1RAP has a great potential as a target molecule for cancer therapy and the formal grant from the EPO is important and strengthens Cantargia's patent portfolio as well as the product candidate CAN04", says Göran Forsberg, CEO at Cantargia.*

### **For further information, please contact**

Göran Forsberg, CEO  
Telephone: +46 (0)46-275 62 60  
E-mail: [goran.forsberg@cantargia.com](mailto:goran.forsberg@cantargia.com)

---

*Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which attacks cancer stem cells as well as mature cancer cells. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, IL1RAP, in cancer stem cells in patients with leukaemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The company has selected a product candidate for future studies in humans. Preclinical trials with Cantargia's antibodies have shown a potent anti-leukemic effect. Parallel studies have shown an even higher expression of IL1RAP in certain solid tumours.*

*Cantargia is listed on NASDAQ First North in Stockholm (ticker: CANTA). Sedermera Fondkommission is Cantargia's Certified Adviser. For more information about Cantargia visit <http://www.cantargia.com>.*